Nonsteroidal immune-modulating therapies and reduced risk of adverse cardiovascular events in dermatomyositis and polymyositis: A cohort study in the All of Us research program

Jill T Shah; Keya T Shah; Soutrik Mandal; Michael S Garshick; Alisa N Femia

doi:10.1016/j.jaad.2024.10.075

Nonsteroidal immune-modulating therapies and reduced risk of adverse cardiovascular events in dermatomyositis and polymyositis: A cohort study in the All of Us research program

J Am Acad Dermatol. 2024 Nov 14:S0190-9622(24)03151-7. doi: 10.1016/j.jaad.2024.10.075. Online ahead of print.

Authors

Jill T Shah¹, Keya T Shah², Soutrik Mandal³, Michael S Garshick⁴, Alisa N Femia⁵

Affiliations

¹ Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.
² Department of Medicine, NYU Langone Long Island Hospital, Mineola, New York.
³ Department of Population Health, NYU Grossman School of Medicine, New York, New York.
⁴ Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York; Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Health, New York, New York.
⁵ Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York. Electronic address: [email protected].

PMID: 39547326
DOI: 10.1016/j.jaad.2024.10.075

No abstract available

Keywords: coronary artery disease; dermatomyositis; heart failure; idiopathic inflammatory myositis; immunomodulatory therapy; major adverse cardiac events; myocardial infarction; polymyositis; stroke.